天康生物(002100.SZ)半年度淨利潤預增912.35%-974.84%
格隆匯 7 月 13日丨天康生物(002100.SZ)公佈,預計2020年半年度歸屬於上市公司股東的淨利潤8.1億元–8.6億元,同比增長912.35%-974.84%。
報告期內,受非洲豬瘟疫情影響,國內生豬供應持續緊張,生豬銷售價格持續高位運行,較上年同期大幅上漲,使得公司食品養殖業務收入及盈利同比均有大幅上升;飼料業務加速產業一體化建設,銷量及利潤均實現較好增長;生物疫苗業務產品盈利能力有較好提升,銷量及利潤較上年實現增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.